綠葉製藥(02186.HK)曾吐13%成交倍增 擬發1.8億美元CB
綠葉製藥(02186.HK)擬發行1.8億美元CB,該股扭兩連漲,今早平開報3.87元欠承接,掉頭跌破20天、50天、100天及20天線(3.57-3.7元),最多挫13%低見3.36元,現報3.46元,回吐10.6%,跑輸同業;成交倍增至6,542萬股,涉資逾2.29億元。
綠葉公布,擬發行1.8億美元年息6.25厘2028年到期可轉換股債券(CB),若獲悉數轉換涉約2.89億股,佔公司擴大後已發行股本約7.13%,初步轉換價每股4.88元(較昨天收市價3.87元溢價約26%),預計所得款項淨額約1.77億美元,擬用於置換其現有債務和產品研發。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.